Previous Page  25 / 32 Next Page
Information
Show Menu
Previous Page 25 / 32 Next Page
Page Background

NMA: improvements in

HRQoL

with AA+P+ADT are

greater than those with D+ADT in patients with HR/HV

mHSPC

Follow-up: LATITUDE – 30.4 months; CHAARTED – unclear

Mean change from baseline in FACT-P total score

1

NMA: improvements in

HRQoL

with AA+P+ADT are

greater than those with D+ADT in patients with HR/HV

mHSPC

Follow-up: LATITUDE – 30.4 months; CHAARTED – unclear

Mean change from baseline in FACT-P total score

1

Feyerabend S et al. Eur J Cancer 2018;doi10.1016/j.ejca.2018.08.

AA, abiraterone acetate; ADT, androgen-deprivation therapy; CrI, credible interval; D, docetaxel; HR, hazard ratio; HRD, high risk

disease; HVD, high volume disease; ITC, indirect treatment comparison; ITT, intent-to-treat; mHSPC, metastatic hormone

sensitive prostate cancer; M1, patients with metastatic disease at randomisation; NDx, newly diagnosed; NMA, network meta-

analysis; P, low-dose prednisone; rPFS, radiographic progression-free survival